PolyPid is a clinical-stage pharmaceutical company focused on developing and commercializing novel, locally administered therapies using its PLEX (Polymer-Lipid Encapsulation matriX) technology. Co.'s product candidates are designed to address unmet medical needs by delivering active pharmaceutical ingredients, or APIs, locally at predetermined release rates and durations over extended periods ranging from days to several months. Co. is initially focused on the development of its lead product candidate, D-PLEX100, which incorporates an antibiotic, for the prevention of surgical site infection in bone and soft tissue. The PYPD stock yearly return is shown above.
The yearly return on the PYPD stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2020 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the PYPD annual return calculation with any dividends reinvested as applicable (on ex-dates).
|